Patrys has today announced the appointment of Dr Charmaine Gittleson as the new Chairman of the Board of Directors.
Dr Gittleson comes to Patrys with an impressive track record in pharmaceutical development, both in Australia and the USA. She is the former Chief Medical Officer of CSL Limited, and her expertise spans many aspects of the pharmaceutical industry, from drug development and clinical research through to strategic planning and executive management. Charmaine also brings extensive regulatory experience to the Board, having successfully worked with regulators in key markets such as the US, EU, Asia Pacific, Japan and South America. Charmaine also has Board and Chairman experience, notably of the ASX-listed company Antisense Therapeutics.
Dr Gittleson said of her appointment:
“I have been following the development of the Patrys platform for several years and continue to be very excited by the potential of deoxymabs to provide new approaches for treating a range of different cancers. As Patrys moves into the next stage of corporate growth and development, I look forward to working with James and his team.”
Dr Gittleson’s appointment will be effective from the close of the Company’s Annual General Meeting today.